Ovarian Cancer Clinical Trial
Official title:
A Randomized, Multicenter, Phase III Study of Erlotinib Versus Observation in Patients With no Evidence of Disease Progression After First Line, Platinum-Based Chemotherapy For High-Risk Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth. Sometimes after treatment, the tumor may not need additional
treatment until it progresses. In this case, observation may be sufficient. It is not yet
known whether erlotinib is more effective than observation after first-line chemotherapy in
treating patients with ovarian cancer, peritoneal cancer, or fallopian tube cancer.
PURPOSE: This randomized phase III trial is studying erlotinib to see how well it works
compared to observation in treating patients who have undergone first-line chemotherapy for
ovarian cancer, peritoneal cancer, or fallopian tube cancer.
Status | Completed |
Enrollment | 835 |
Est. completion date | |
Est. primary completion date | February 2008 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility |
DISEASE CHARACTERISTICS: - Histologically confirmed ovarian epithelial, primary peritoneal, or fallopian tube cancer meeting 1 of the following criteria: - High-risk stage I disease, as defined by grade 3, aneuploid grade 1 or 2, or clear cell disease - Stage II, III, or IV disease - Completed first-line therapy within the past 6 weeks - Received a platinum derivative (carboplatin or cisplatin) alone or in combination with other agents for 6-9 courses - Must have achieved complete response/no evidence of disease, partial response, or stabilization of disease after therapy - No adenocarcinoma of unknown origin - No known brain metastases or leptomeningeal disease PATIENT CHARACTERISTICS: Performance status - ECOG 0-1 Life expectancy - Not specified Hematopoietic - Platelet count = 100,000/mm^3 - WBC = 2,000/mm^3 Hepatic - AST and ALT = 2.5 times upper limit of normal (ULN) (= 5 times ULN in patients with known liver metastases) - Bilirubin = 1.5 times ULN - Alkaline phosphatase = 5 times ULN except in patients with known bone metastases - PT and PTT = 1.5 times ULN Renal - Creatinine = 2 times ULN Cardiovascular - No myocardial infarction within past 6 months - No second- or third-degree heart block without pacemaker Gastrointestinal - No active peptic ulcer disease - No gastrointestinal tract disease that would interfere with ability to take oral medications, affect absorption, or require parenteral nutrition - No uncontrolled inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis) Other - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - No significant dermatologic disease - No inflammatory changes to the surface of the eye - No history of allergic reaction to compounds of similar chemical composition as erlotinib - No other significant medical condition or neurologic or psychiatric disorder - No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or cone-biopsied carcinoma in situ of the cervix - No psychiatric illness or familial, geographic, or social situation that would preclude study compliance PRIOR CONCURRENT THERAPY: Biologic therapy - No prior therapy targeting epidermal growth factor receptor - No concurrent immunotherapy Chemotherapy - See Disease Characteristics - See Surgery - No concurrent chemotherapy Endocrine therapy - No concurrent hormonal therapy Radiotherapy - No prior radiotherapy unless completed more than 5 years ago AND outside the abdomen/pelvis Surgery - Interval debulking surgery after 3 courses of chemotherapy and second-look surgery at the end of chemotherapy allowed as per study EORTC-55971/NCIC OV13/Chorus Other - No other prior or concurrent investigational agents - No other concurrent anticancer treatment - Concurrent participation in study EORTC-55971/NCIC-OV13/Chorus allowed |
Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Australia | Royal Brisbane and Women's Hospital | Brisbane | Queensland |
Australia | Royal Women's Hospital | Carlton | Victoria |
Australia | Frankston Hospital | Frankston | Victoria |
Australia | Sir Charles Gairdner Hospital - Nedlands | Nedlands | Western Australia |
Australia | Prince of Wales Private Hospital | Randwick | New South Wales |
Australia | Tamworth Base Hospital | Tamworth | New South Wales |
Australia | Manning Base Hospital | Taree | New South Wales |
Australia | Newcastle Mater Misericordiae Hospital | Waratah | New South Wales |
Australia | Murray Valley Private Hospital and Cancer Treatment Centre | Wodonga | Victoria |
Austria | Landeskrankenhaus Klagenfurt | Klagenfurt | |
Austria | A.o. Bezirkskrankenhaus Kufstein | Kufstein | |
France | Centre Hospitalier de L' Agglomeration Montargoise | Amilly | |
France | Centre Hospitalier General | Amilly | |
France | Centre Hospital General Robert Ballanger | Aulnay Sous Bois | |
France | Centre Hospitalier Regional de Besancon - Hopital Jean Minjoz | Besancon | |
France | Clinique Tivoli | Bordeaux | |
France | Institut Bergonie | Bordeaux | |
France | Polyclinique Bordeaux Nord Aquitaine | Boucher | |
France | Centre Regional Francois Baclesse | Caen | |
France | Centre Hospitalier Regional de Chambery | Chambery | |
France | Centre Jean Perrin | Clermont-Ferrand | |
France | Hopital Louis Pasteur | Colmar | |
France | Centre Hospitalier de Dax | Dax | |
France | Clinique Pasteur | Evreux | |
France | Centre Hospitalier de Gap | Gap | |
France | Centre Hospitalier Departemental | La Roche Sur Yon | |
France | Clinique Victor Hugo | Le Mans | |
France | Centre Hospitalier Bretagne Sud | Lorient | |
France | Centre Leon Berard | Lyon | |
France | Hopital Saint Joseph | Marseille | |
France | Centre Hospitalier General de Mont de Marsan | Mont-de-Marsan | |
France | Centre Hospitalier General Andre Boulloche | Montbeliard | |
France | Centre Hospitalier de Montlucon | Montlucon | |
France | Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle | Montpellier | |
France | Hotel Dieu de Paris | Paris | |
France | Institut Curie Hopital | Paris | |
France | Polyclinique Francheville | Perigueux | |
France | Centre Hospitalier Lyon Sud | Pierre Benite | |
France | CHU Poitiers | Poitiers | |
France | Institut Jean Godinot | Reims | |
France | Centre Eugene Marquis | Rennes | |
France | Clinique Armoricaine De Radiologie | Saint Brieuc | |
France | Centre Paul Strauss | Strasbourg | |
France | Hopitaux Universitaire de Strasbourg | Strasbourg | |
France | Centre Hospitalier Universitaire Bretonneau de Tours | Tours | |
France | Centre Hospitalier Valence | Valence | |
France | Centre Alexis Vautrin | Vandoeuvre-les-Nancy | |
Italy | Centro di Riferimento Oncologico - Aviano | Aviano | |
Italy | Ospedale Sant Anna | Como | |
Italy | Ospedale Santa Maria Goretti | Latina | |
Italy | Ospedale Niguarda Ca'Granda | Milan | |
Italy | Ospedale San Gerardo | Monza | |
Italy | Azienda Sanitaria Ospedaliera Ordine Mauriziano | Turin | |
Italy | Universita di Torino | Turin | |
Italy | Ospedale di Circolo e Fondazione Macchi | Varese | |
Netherlands | Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital | Amsterdam | |
Netherlands | Onze Lieve Vrouwe Gasthuis | Amsterdam | |
Netherlands | Martini Ziekenhuis | Groningen | |
Netherlands | Leiden University Medical Center | Leiden | |
Netherlands | Universitair Medisch Centrum St. Radboud - Nijmegen | Nijmegen | |
Netherlands | Erasmus MC - Sophia Children's Hospital | Rotterdam | |
Portugal | Hospitais da Universidade de Coimbra (HUC) | Coimbra | |
Spain | Institut d'Oncologia Corachan | Barcelona | |
Spain | Hospital Universitario 12 de Octubre | Madrid | |
Spain | Hospital Universitario San Carlos | Madrid | |
Spain | Hospital Universitario Central de Asturias | Oviedo | |
Spain | Instituto Valenciano De Oncologia | Valencia | |
United Kingdom | Bronglais District General Hospital | Aberystwyth | Wales |
United Kingdom | Stoke Mandeville Hospital | Aylesbury-Buckinghamshire | England |
United Kingdom | North Devon District Hospital | Barnstaple | England |
United Kingdom | Royal United Hospital | Bath | England |
United Kingdom | City Hospital - Birmingham | Birmingham | England |
United Kingdom | Velindre Cancer Center at Velindre Hospital | Cardiff | Wales |
United Kingdom | Cumberland Infirmary | Carlisle | England |
United Kingdom | Queen Elizabeth Hospital | Gateshead | England |
United Kingdom | Gartnavel General Hospital | Glasgow | Scotland |
United Kingdom | Ipswich Hospital | Ipswich | England |
United Kingdom | University College Hospital | London | England |
United Kingdom | Mid Kent Oncology Centre at Maidstone Hospital | Maidstone | England |
United Kingdom | Queen Elizabeth The Queen Mother Hospital | Margate | England |
United Kingdom | Clatterbridge Centre for Oncology | Merseyside | England |
United Kingdom | James Cook University Hospital | Middlesbrough | England |
United Kingdom | St. Mary's Hospital | Newport | England |
United Kingdom | Mount Vernon Cancer Centre at Mount Vernon Hospital | Northwood | England |
United Kingdom | Norfolk and Norwich University Hospital | Norwich | England |
United Kingdom | Royal Preston Hospital | Preston | England |
United Kingdom | Royal Shrewsbury Hospital | Shrewsbury | England |
United Kingdom | Wexham Park Hospital | Slough, Berkshire | England |
United Kingdom | Southampton General Hospital | Southampton | England |
United Kingdom | Staffordshire General Hospital | Stafford | England |
United Kingdom | South West Wales Cancer Institute | Swansea | Wales |
United Kingdom | Yeovil District Hospital | Yeovil | England |
Lead Sponsor | Collaborator |
---|---|
European Organisation for Research and Treatment of Cancer - EORTC |
Australia, Austria, France, Italy, Netherlands, Portugal, Spain, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Progression-free survival | No | ||
Secondary | Overall survival | No | ||
Secondary | Adverse event profile | Yes | ||
Secondary | Quality of life | No | ||
Secondary | Cutaneous toxicity (rash or acne [papulo-pustular rash]) | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Withdrawn |
NCT05201001 -
APX005M in Patients With Recurrent Ovarian Cancer
|
Phase 2 | |
Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT05156892 -
Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer
|
Phase 1 | |
Suspended |
NCT02432378 -
Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines
|
Phase 1/Phase 2 | |
Recruiting |
NCT04533763 -
Living WELL: A Web-Based Program for Ovarian Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT03371693 -
Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer
|
Phase 3 | |
Withdrawn |
NCT03032614 -
Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients
|
Phase 2 | |
Completed |
NCT01936363 -
Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer
|
Phase 2 | |
Completed |
NCT02019524 -
Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients
|
Phase 1 | |
Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05059522 -
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
|
Phase 3 | |
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Terminated |
NCT04586335 -
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
|
Phase 1 | |
Terminated |
NCT03146663 -
NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer
|
Phase 2 |